Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the commercialization of FYB206 in the defined territories
The study met its primary endpoint and all 11 secondary efficacy endpoints
The EMBOLD study evaluated relutrigine for patients with SCN2A and SCN8A developmental and epileptic encephalopathies
Peapod Bio’s proprietary technologies can efficiently identify inhibitors and binding molecules for virtually any target
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
Here's a development that aims to keep your blood pressure in check. Literally!
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
Subscribe To Our Newsletter & Stay Updated
